NASDAQ:CCCC C4 Therapeutics (CCCC) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free CCCC Stock Alerts $6.47 -0.43 (-6.23%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$6.46▼$6.9950-Day Range$6.47▼$11.0052-Week Range$1.06▼$11.88Volume1.04 million shsAverage Volume1.27 million shsMarket Capitalization$443.84 millionP/E RatioN/ADividend YieldN/APrice Target$10.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get C4 Therapeutics alerts: Email Address C4 Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside58.4% Upside$10.25 Price TargetShort InterestBearish13.34% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.86) to ($2.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.68 out of 5 starsMedical Sector836th out of 907 stocksBiological Products, Except Diagnostic Industry147th out of 153 stocks 3.3 Analyst's Opinion Consensus RatingC4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageC4 Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.34% of the outstanding shares of C4 Therapeutics have been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in C4 Therapeutics has recently increased by 72.97%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldC4 Therapeutics does not currently pay a dividend.Dividend GrowthC4 Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CCCC. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 19 people have searched for CCCC on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added C4 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, C4 Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.97% of the stock of C4 Therapeutics is held by insiders.Percentage Held by Institutions78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.86) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of C4 Therapeutics is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of C4 Therapeutics is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioC4 Therapeutics has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About C4 Therapeutics Stock (NASDAQ:CCCC)C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Read More CCCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CCCC Stock News HeadlinesApril 11, 2024 | seekingalpha.comArvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win SituationApril 9, 2024 | globenewswire.comC4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology ForumApril 25, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 8, 2024 | msn.comC4 Dips on Release of DataApril 8, 2024 | finance.yahoo.comC4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024April 8, 2024 | globenewswire.comC4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024March 28, 2024 | finance.yahoo.comHere’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)March 16, 2024 | finance.yahoo.comCCCC Mar 2024 17.000 callApril 25, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 16, 2024 | finance.yahoo.comCCCC Mar 2024 10.000 putMarch 9, 2024 | nasdaq.comGuru Fundamental Report for CCCCMarch 5, 2024 | globenewswire.comC4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024March 4, 2024 | globenewswire.comC4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic ProteinsMarch 2, 2024 | finance.yahoo.comCCCC Mar 2024 9.000 callMarch 1, 2024 | seekingalpha.comC4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains StretchedFebruary 27, 2024 | finance.yahoo.comNew Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)February 26, 2024 | markets.businessinsider.comBreaking Down C4 Therapeutics: 4 Analysts Share Their ViewsFebruary 25, 2024 | finance.yahoo.comCCCC Mar 2024 8.500 putFebruary 24, 2024 | ca.finance.yahoo.comCCCC Mar 2024 7.000 putFebruary 24, 2024 | finance.yahoo.comC4 Therapeutics Full Year 2023 Earnings: Misses ExpectationsFebruary 23, 2024 | markets.businessinsider.comStrong Financials and Promising Drug Pipeline Bolster Buy Rating for C4 TherapeuticsFebruary 23, 2024 | realmoney.thestreet.comC4 Therapeutics price target raised by $1 at Stifel, here's whyFebruary 22, 2024 | benzinga.comC4 Therapeutics Stock (NASDAQ:CCCC) Insider TradesFebruary 22, 2024 | finanznachrichten.deC4 Therapeutics, Inc.: C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsFebruary 22, 2024 | finance.yahoo.comC4 Therapeutics Inc (CCCC) Reports Full Year 2023 Financial Results and Business UpdatesFebruary 22, 2024 | finance.yahoo.comC4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsFebruary 22, 2024 | globenewswire.comC4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsSee More Headlines Receive CCCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/25/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CCCC CUSIPN/A CIK1662579 Webwww.c4therapeutics.com Phone617-231-0700FaxN/AEmployees145Year FoundedN/APrice Target and Rating Average Stock Price Target$10.25 High Stock Price Target$20.00 Low Stock Price Target$2.00 Potential Upside/Downside+58.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-132,490,000.00 Net Margins-638.34% Pretax Margin-632.17% Return on Equity-55.30% Return on Assets-35.80% Debt Debt-to-Equity RatioN/A Current Ratio6.34 Quick Ratio6.34 Sales & Book Value Annual Sales$20.76 million Price / Sales21.38 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / Book1.59Miscellaneous Outstanding Shares68,600,000Free Float63,134,000Market Cap$443.84 million OptionableOptionable Beta3.18 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Andrew J. Hirsch M.B.A. (Age 53)CEO, President & Director Comp: $971kDr. Kenneth C. Anderson M.D. (Age 73)Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board Comp: $39.03kDr. Stewart Fisher (Age 57)Chief Scientific Officer Comp: $657.34kMr. Scott N. Boyle M.B.A. (Age 46)Ph.D., Chief Business Officer Comp: $672.78kDr. Nathanael S. Gray Ph.D.Co-Founder & Member of Scientific Advisory BoardMs. Kendra AdamsChief Financial OfficerMr. Mark Mossler (Age 51)Chief Accounting Officer Ms. Jolie M. Siegel J.D. (Age 47)Chief Legal Officer & Corporate Secretary Comp: $610.4kMs. Kelly A. Schick (Age 44)Chief People Officer Dr. Isabel Chiu Ph.D.Senior Vice President of Strategic Alliances & Business DevelopmentMore ExecutivesKey CompetitorsTaysha Gene TherapiesNASDAQ:TSHAHumacyteNASDAQ:HUMAEditas MedicineNASDAQ:EDITAlectorNASDAQ:ALECFate TherapeuticsNASDAQ:FATEView All CompetitorsInstitutional OwnershipWasatch Advisors LPSold 2,810,470 shares on 4/18/2024Ownership: 6.310%Wasatch Advisors LPBought 891,808 shares on 2/14/2024Ownership: 14.487%Commodore Capital LPBought 3,800,000 shares on 2/14/2024Ownership: 7.711%Bellevue Group AGBought 62,000 shares on 2/14/2024Ownership: 0.126%Lighthouse Investment Partners LLCBought 21,981 shares on 2/14/2024Ownership: 0.045%View All Institutional Transactions CCCC Stock Analysis - Frequently Asked Questions Should I buy or sell C4 Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CCCC shares. View CCCC analyst ratings or view top-rated stocks. What is C4 Therapeutics' stock price target for 2024? 6 brokerages have issued 1 year price targets for C4 Therapeutics' stock. Their CCCC share price targets range from $2.00 to $20.00. On average, they expect the company's share price to reach $10.25 in the next twelve months. This suggests a possible upside of 58.4% from the stock's current price. View analysts price targets for CCCC or view top-rated stocks among Wall Street analysts. How have CCCC shares performed in 2024? C4 Therapeutics' stock was trading at $5.65 at the beginning of the year. Since then, CCCC stock has increased by 14.5% and is now trading at $6.47. View the best growth stocks for 2024 here. Are investors shorting C4 Therapeutics? C4 Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,150,000 shares, an increase of 73.0% from the March 15th total of 5,290,000 shares. Based on an average daily volume of 3,740,000 shares, the days-to-cover ratio is presently 2.4 days. View C4 Therapeutics' Short Interest. When is C4 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CCCC earnings forecast. How were C4 Therapeutics' earnings last quarter? C4 Therapeutics, Inc. (NASDAQ:CCCC) issued its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.01. The company earned $3.26 million during the quarter, compared to the consensus estimate of $5.23 million. C4 Therapeutics had a negative net margin of 638.34% and a negative trailing twelve-month return on equity of 55.30%. When did C4 Therapeutics IPO? C4 Therapeutics (CCCC) raised $150 million in an initial public offering on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO. Who are C4 Therapeutics' major shareholders? C4 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Wasatch Advisors LP (6.31%). Insiders that own company stock include Adam Crystal, Andrew Hirsch, Elena Prokupets, Jolie Siegel, Malcolm Salter, Stewart Fisher and Utpal Koppikar. View institutional ownership trends. How do I buy shares of C4 Therapeutics? Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CCCC) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.